Research programme: CC-chemokine receptor 3 antagonists - Astellas Pharma/Toray IndustriesAlternative Names: YM-344484; YM-355179
Latest Information Update: 16 Jul 2016
At a glance
- Originator Astellas Pharma; Toray
- Mechanism of Action CCR3 receptor antagonists; Histamine H1 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Asthma; Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in Japan (PO)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Japan (PO)
- 09 Aug 2006 Preclinical trials in Inflammation in Japan (PO)